Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Advanced Chordoma
NCT03083678Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Jun 2018
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of afatinib in chordoma, sponsored by Leiden University Medical Center. Primary endpoints: Median Progression-Free Survival according to RECIST 1.1 (First-line cohort) at 1 year, Median Progression-Free Survival according to RECIST 1.1 (Second or later line cohort) at 1 year and 2 more. Started Jun 2018; status: completed.
02
Drugs
afatinib
03
Conditions
chordoma
Beyond the preview
Go deeper on NCT03083678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083678.